SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program
- Dr. Favre brings extensive experience in gene therapy, immunology and drug development
- Appointment comes at a pivotal time of Company growth as it prepares for clinical development and expands its pipeline into other gene therapies
BARCELONA, June 20, 2023 – SpliceBio, a genetic medicines company exploiting its proprietary Protein Splicing platform to develop next generation gene therapies, is pleased to announce the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer (CDO).
